Bayer HealthCare's 'Xofigo' (ingredient: radium-223 chloride) received permission to treat prostate

Published: 2014-02-07 06:58:00

Updated: 2014-02-07 06:58:00

Bayer HealthCare's 'Xofigo' (ingredient: radium-223 chloride) received permission to treat prostate cancer with symptomatic and bone metastasis in domestic

(Yakup Shinmoon)

Bayer HealthCare's 'Xofigo' (ingredient: radium-223 chloride) received permission to treat prostate cancer with symptomatic and bone metastasis except visceral metastasis in domestic.

This domestic approval based on...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.